From the China Compliance Digest (Issue No. 8: March 26, 2012):
Officials in the southern province of Yunnan announced the approval of regulatory changes designed to stem medical corruption, including the introduction of a blacklist of bribery offenders.
Facilities, companies, and personnel implicated in corruption will be ineligible for official commendations. In addition, doctors involved in serious corruption cases may have their medical licenses revoked.
Pharmaceutical companies involved in serious corruption cases will be barred from submitting products to the health department for approval.
Source: Health Paper (健康报)
For a limited time, subscribers to the FCPA Blog will receive a complimentary one-month subscription to the China Compliance Digest. Subscribe to the FCPA Blog by filling in the box on the left under ‘Connect.’